Search results
Added:
1 week ago
Author(s):
Narra Lavanya
,
Abraham Oomman
Added:
1 month ago
Author(s):
Brian Lindman
Added:
1 month ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in…
View more
Author(s):
Kevin Lee
,
Iva Minga
,
Eryn Cameron
,
et al
Added:
1 year ago
Author(s):
Diana Hui Ping Foo
Added:
5 days ago
ESC HF 25 - Findings from Heart2Miss suggest a hub-and-spoke model for early heart failure detection can detect patients with pre-HF and HF who were previously undiagnosed, can reduce tertiary center overload and improve novice performance.Dr Diana Foo (Sarawak General Hospital, Kuching, MY) discusses the findings from the Heart2Miss study, investigating a decentralised, community-based, rapid,…
View more
Author(s):
Kaoutar Kabbadj
,
Nora Taiek
,
Wiame El Hjouji
,
et al
Added:
5 months ago
Author(s):
Christine Shen
,
Sanjeev P Bhavnani
,
John D Rogers
Added:
10 months ago
Author(s):
Sarah Godfrey
,
Alexis Barnes
,
Jing Gao
,
et al
Added:
8 months ago
Author(s):
Domingo Figal
Added:
2 years ago
ESC-HFA 2023 — Prof Domingo Pascual Figal (Hospital Clinico Universitario Virgen de la Arrixaca, SP) discusses the DAPA MODA study (NCT04707352).
The study aimed to assess the effects of dapagliflozin on cardiac remodeling parameters, particularly LA geometry and function, and biomarkers reflecting pathophysiological pathways. Findings from ESC Heart Failure 2023 revealed that dapagliflozin…
View more
Author(s):
Marianna Fontana
Added:
2 years ago
ESC-HFA 23 — We are joined by Prof Marianna Fontana (University College London, UK), as she outlines the key findings from the phase 3 APOLLO-B study (Alnylam Pharmaceuticals) (NCT03997383).
APOLLO-B investigated the use of patisiran, a transthyretin-directed small interfering RNA, in a cohort of patients with cardiac amyloidosis. 360 patients were enrolled in the trial and were randomized 1:1…
View more